Group 1 - The article highlights the stock recommendations from various securities firms, with a total of 21 listed companies receiving recommendations on February 25 [2] - Supor received the highest number of recommendations, with three firms suggesting a buy, while companies like Yuheng Pharmaceutical and Bohai Leasing received one recommendation each [2] - The recommended target prices and potential price increases for the stocks include Supor at 60.45 with a potential increase of 34.84%, and Yuheng Pharmaceutical at 3.64 with a potential increase of 6.74% [2] Group 2 - On February 25, eight companies received initial coverage from securities firms, with Hongchuan Wisdom rated as "Buy" by Huayuan Securities [4] - Other companies receiving "Buy" ratings include Runben Co. by Dongguan Securities, Qianyan Bio by Changjiang Securities, and Zhongtian Technology by Zhongyou Securities [4][5] - The sectors represented in the initial coverage include logistics, personal care products, chemical pharmaceuticals, communication equipment, and photovoltaic equipment [5]

Core Viewpoint - The report emphasizes the importance of capturing structural opportunities in the pharmaceutical sector, particularly focusing on medical/healthcare AI and stocks with positive fundamental changes [1] Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries this week [1] - The medical services sector increased by 0.22%, while the chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce sectors fell by 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [1] Investment Opportunities - The pharmaceutical market is showing clear segmentation, with AI healthcare, small nucleic acid-related stocks that have recently corrected, and stocks with marginal fundamental changes and lighter institutional holdings performing well [1] - The pharmaceutical sector, combining technology and consumer attributes, is expected to continue exhibiting structural trends amid market rotations [1] - The innovative drug sector has experienced a significant rise followed by a correction over the past year, with valuations generally considered reasonable compared to early 2025 levels [1] Recommended Focus Areas - It is advised to pay attention to specific sub-sectors such as small nucleic acids, in vivo CAR, ADC, second-generation IO, and PROTAC, as well as companies with marginal fundamental changes that are likely to realize sustained performance [1] - The medical/healthcare AI+ sector is highlighted as a recently popular direction, suggesting a focus on leading companies in this field, as well as those with non-pharmaceutical/healthcare AI+ core businesses that are actively embracing related technologies and expected to realize valuation flexibility in the short to medium term [1] - In the consumer aspect, with 2025 performance forecasts largely reflected in current stock prices, attention is recommended on traditional Chinese medicine and medical beauty sectors that are actively expanding their product offerings, as well as the medical services sector that has undergone long-term adjustments [1]

Core Viewpoint - The pharmaceutical sector, characterized by both technology and consumer attributes, is expected to continue exhibiting structural trends amid market fluctuations, with a focus on innovative drug segments and emerging technologies like AI in healthcare [1][2]. Group 1: Market Performance - The Shanghai and Shenzhen 300 index rose by 0.36%, while the pharmaceutical and biological sector declined by 0.81%, ranking 21st among 31 primary sub-industries [2][4]. - The medical services sector increased by 0.22%, while chemical pharmaceuticals, biological products, medical devices, traditional Chinese medicine, and pharmaceutical commerce saw declines of 0.54%, 0.89%, 1.07%, 1.75%, and 2.68% respectively [2][4]. Group 2: Investment Recommendations - Companies are advised to focus on sectors with positive fundamental changes and light institutional holdings, particularly in the AI healthcare and small nucleic acid segments, which have shown strong performance [2][3]. - The report suggests monitoring companies that are not primarily in the pharmaceutical/medical AI+ sector but are actively adopting related technologies with potential for short-term valuation flexibility [2]. Group 3: In Vivo CAR Developments - Multiple clinical studies for in vivo CAR are expected to reach major endpoints within the year, particularly those targeting autoimmune indications, indicating significant potential for this cutting-edge technology [3][4]. - Abbvie's acquisition of Capstan for $21 billion is highlighted, with its core pipeline expected to reach major clinical endpoints soon, focusing on safety and immune response indicators, which could pave the way for further development in autoimmune indications [4]. Group 4: Overall Sector Analysis - The pharmaceutical sector has yielded a return of 2.44% since early 2026, outperforming the Shanghai and Shenzhen 300 index by 1.79 percentage points [4].

Core Insights - The trend of increasing market makers is effectively improving the overall trading landscape of the New Third Board market, with market makers contributing over 50% of the total trading volume despite representing only 3.35% of the total number of companies listed [1][4]. Group 1: Market Maker Activity - Since 2025, over 30 listed companies have disclosed the addition of brokers providing market-making services, with 9 companies adding more than 3 new market makers [1]. - Companies such as Hengshen Co., Yajing Technology, and Shengzhao Pharmaceuticals have recently disclosed the addition of brokers, with Zhongbing Communication seeing a significant increase of 4 new market makers [1][2]. - Click Network has increased its market makers to 12, while Shengzhao Pharmaceuticals has added 5 new market makers, bringing its total to 11 [2][3]. Group 2: Trading Volume and Liquidity - Companies with more than 10 market makers have seen enhanced trading depth and liquidity, with 18 companies currently fitting this criterion [1][4]. - The top companies in terms of market maker numbers include Huachuang Fangte, which has 29 brokers providing services [4]. - The trading activity of companies like Jufeng Co. and Yajing Technology has been notable, with Jufeng achieving a compound annual growth rate of 37.78% in net profit from 2022 to 2024 [3]. Group 3: Regulatory and Market Support - The National Equities Exchange and Quotations (NEEQ) has been optimizing information disclosure and service levels to attract attention to quality market-making targets [4][5]. - A new section on the NEEQ website showcases the top 50 companies with the highest average daily trading volume over the past 60 days, aiding investors in tracking market activity [5]. - Market makers are enhancing market liquidity and pricing efficiency through bilateral quotes, which helps stabilize the market [5].

Group 1 - The stock price of *ST Jingfeng (000908) closed at 6.52 yuan on February 25, 2026, down 1.66%, with a turnover rate of 1.9% and a trading volume of 167,000 hands, resulting in a transaction amount of 109 million yuan [1][2] - On February 25, 2026, the net outflow of main funds was 11.613 million yuan, indicating a trend of large capital exiting the market [2] - The company received approval for its restructuring plan from the Changde Intermediate People's Court in Hunan Province, which will increase the total share capital to 1,759,548,702 shares through a capital reserve transfer, with potential downward adjustment risks for the stock price [1][2] Group 2 - The capital reserve transfer will not allocate additional shares to existing shareholders, as all shares will be acquired by restructuring investors for paying bankruptcy costs, settling debts, and supplementing working capital [1] - The company warns investors of the risk of downward adjustment if the stock price exceeds 2.34 yuan per share on the record date [1]

Core Viewpoint - The company, Hanyu Pharmaceutical, anticipates a significant improvement in its financial performance for the year 2025, with projected revenues between 950 million and 980 million yuan and a return to profitability with net profits estimated between 40 million and 50 million yuan [1] Financial Performance - For the year 2025, the company expects to achieve operating revenue of 950 million to 980 million yuan [1] - The company forecasts a net profit of 40 million to 50 million yuan, indicating a turnaround from previous losses [1] Strategic Initiatives - In the second half of 2025, the company plans to increase its research and development investments, capacity building, and international expansion to capitalize on the rapid growth opportunities in the GLP-1 global market [1] - The related expenses for these strategic initiatives will be concentrated, but the company maintains a positive outlook on its core business and sufficient operating cash flow [1]

Core Viewpoint - The company announced that its subsidiary, Zhejiang Anglikang Animal Health Technology Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs for a veterinary drug product, "Inhalation Sevoflurane (for pets)," which is now ready for market sales [2]. Group 1 - The approved veterinary drug has the product approval number 111187016 and comes in a specification of 120ml [2]. - The product is intended for use in pet surgical anesthesia induction and maintenance [2]. - The approval is valid until February 8, 2031, indicating a long-term market presence [2].

Group 1 - Company Hainan Haiyao announced that its 31st meeting of the 11th board of directors was held on February 25, 2026, via communication voting [1] - The meeting reviewed the proposal regarding the convening of the first temporary shareholders' meeting in 2026 [1]

Group 1 - The core announcement is that Jincheng Pharmaceutical has received drug registration certificates for two products from the National Medical Products Administration [2] - The products include Bisoprolol Amlodipine Tablets and Cefdinir Dry Suspension, which are now officially registered for sale [2] - The registration is a significant step for the company's subsidiaries, Beijing Jincheng Tail Pharmaceutical Co., Ltd. and Shanghai Jincheng Suzhizhi Pharmaceutical Co., Ltd. [2]

Group 1 - The core viewpoint of the article highlights that the company, Lianhua Technology, is committed to providing end-to-end integrated services in its pharmaceutical business, continuously striving to enhance its business capabilities in line with customer development [2] Group 2 - The company engages with investors through interactive platforms, indicating a focus on transparency and communication with stakeholders [2] - The emphasis on improving business levels suggests a proactive approach to adapting to market demands and customer needs [2]